News

Consequently, Teva is licensed to launch a generic version of Victoza as of 22 December 2023. Under certain circumstances Teva could launch a generic version of Victoza earlier,

Under the agreement, twoXAR will use its proprietary artificial intelligence (AI ) technology to identify a set of lead compounds which demonstrate a novel mechanism of action and

Tecentriq monoclonal antibody has been approved in combination with carboplatin and etoposide as a first-line treatment for adults with ES-SCLC. The approval was based on data from the

The fundraise was co-led by new investors OrbiMed Advisors and Arix Bioscience plc and included investment from RA Capital and Rock Springs Capital. Existing investors New Enterprise Associates,

Extensive blistering can lead to serious, life-threatening fluid loss, infection and/or death. MabThera is the first biologic therapy approved by the European Commission for PV and the first

Based in Tokyo, Ayumi is engaged in the manufacturing and marketing of various drug products for anti-rheumatism and orthopedic pain management. Citing a person familiar with the matter,

The findings of the study, called European Sudden Cardiac Arrest network (ESCAPE-NET), were presented at European Heart Rhythm Association (EHRA) 2019. It evaluated if nifedipine and amlodipine –

Hereditary Spinocerebellar Ataxias are rare, potentially fatal neurodegenerative disorders affecting the cerebellum. They are characterized clinically by progressive ataxia symptoms, including difficulties with balance, speech, and coordination, and

Under The collaboration agreement will enable Merck to use Iktos generative modelling AI technology to facilitate the rapid and cost-effective discovery and design of new compounds. The agreement